Table 8—

Study design and clinical outcomes in azithromycin in cystic fibrosis randomised controlled trials

Wolter 2Equi 3Saiman 4Clement 5
Study design
 CountryAustraliaUKUSAFrance
 Patients n604118582
 PopulationAdultPaediatricAdult/paediatricAdult/paediatric
 Duration months315#612
 Dosing regimen250 mg·day−1500 mg·day−1¶500 mg MWF500 mg MWF
Clinical outcomes
 Baseline FEV1 % pred57617085
 Relative % change in FEV1 % pred+3.6+5.4+6.2−4.3
 Hospital daysNR
 Intravenous antibiotic days+
 Inflammatory markersNR
 QoL§ƒ
  • FEV1: forced expiratory volume in one second; % pred: % predicted; QoL: quality of life; MWF: Monday, Wednesday, Friday (days of administration); NR: not reported; ↓: decreased; ↔: unchanged; ↑: increased. #: 1-month run-in, 6 months each cycle (azithromycin/placebo), 2-month washout period; : 250 mg for patients <40 kg; +: intravenous antibiotic courses (instead of days); §: quality of well being visual analogue score reported; ƒ: physical functioning domain significantly increased (other domains unchanged).